WO2006039663A2 - Methods for the administration of iloperidone - Google Patents
Methods for the administration of iloperidone Download PDFInfo
- Publication number
- WO2006039663A2 WO2006039663A2 PCT/US2005/035526 US2005035526W WO2006039663A2 WO 2006039663 A2 WO2006039663 A2 WO 2006039663A2 US 2005035526 W US2005035526 W US 2005035526W WO 2006039663 A2 WO2006039663 A2 WO 2006039663A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iloperidone
- patient
- cyp2d6
- acceptable salt
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/576,178 US8586610B2 (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
EP05803436A EP1799865B1 (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
CA2582022A CA2582022C (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
EP12164353.0A EP2479290B1 (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
AU2005292246A AU2005292246B2 (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
JP2007534871A JP2008514731A (en) | 2004-09-30 | 2005-09-30 | How to administer iloperidone |
US14/044,183 US20140039008A1 (en) | 2004-09-30 | 2013-10-02 | Methods for the administration of iloperidone |
US14/060,978 US20140045893A1 (en) | 2004-09-30 | 2013-10-23 | Methods for the administration of iloperidone |
US14/150,575 US9138432B2 (en) | 2004-09-30 | 2014-01-08 | Methods for the administration of iloperidone |
US14/710,817 US20150258083A1 (en) | 2004-09-30 | 2015-05-13 | Methods for the administration of iloperidone |
US14/847,784 US20160053324A1 (en) | 2004-09-30 | 2015-09-08 | Methods for the administration of iloperidone |
US15/835,872 US10272076B2 (en) | 2004-09-30 | 2017-12-08 | Methods for the administration of iloperidone |
US16/286,878 US20190183873A1 (en) | 2004-09-30 | 2019-02-27 | Methods for the administration of iloperidone |
US16/406,229 US20190360047A1 (en) | 2004-09-30 | 2019-05-08 | Methods for the administration of iloperidone |
US16/818,113 US20200206213A1 (en) | 2004-09-30 | 2020-03-13 | Methods for the administration of iloperidone |
US17/190,934 US20210186948A1 (en) | 2004-09-30 | 2021-03-03 | Methods for the administration of iloperidone |
US18/317,881 US20230330078A1 (en) | 2004-09-30 | 2023-05-15 | Methods for the administration of iloperidone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61479804P | 2004-09-30 | 2004-09-30 | |
US60/614,798 | 2004-09-30 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/576,178 A-371-Of-International US8586610B2 (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
US12/208,027 Continuation-In-Part US20100063093A1 (en) | 2004-09-30 | 2008-09-10 | Methods for the administration of iloperidone |
US14/060,978 Continuation US20140045893A1 (en) | 2004-09-30 | 2013-10-23 | Methods for the administration of iloperidone |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006039663A2 true WO2006039663A2 (en) | 2006-04-13 |
WO2006039663A3 WO2006039663A3 (en) | 2006-11-02 |
Family
ID=36143143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/035526 WO2006039663A2 (en) | 2004-09-30 | 2005-09-30 | Methods for the administration of iloperidone |
Country Status (7)
Country | Link |
---|---|
US (9) | US8586610B2 (en) |
EP (2) | EP1799865B1 (en) |
JP (2) | JP2008514731A (en) |
AU (1) | AU2005292246B2 (en) |
CA (2) | CA2582022C (en) |
ES (1) | ES2825949T3 (en) |
WO (1) | WO2006039663A2 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137227A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
WO2008121899A2 (en) | 2007-03-29 | 2008-10-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
WO2008144599A3 (en) * | 2007-05-18 | 2009-01-29 | Vanda Pharmaceuticals Inc | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
WO2009036056A1 (en) * | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
WO2009076664A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
WO2009076663A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
WO2010030783A1 (en) | 2008-09-10 | 2010-03-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
WO2010117931A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
WO2010117941A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
WO2010117943A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof |
WO2010117937A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation |
WO2010132866A1 (en) * | 2009-05-15 | 2010-11-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
JP2010538617A (en) * | 2007-09-10 | 2010-12-16 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Prediction of QT prolongation based on SNP genotype |
US8198305B2 (en) | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
WO2013138602A1 (en) | 2012-03-14 | 2013-09-19 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
US8586610B2 (en) | 2004-09-30 | 2013-11-19 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
CN104254917A (en) * | 2012-03-26 | 2014-12-31 | 先进封装技术私人有限公司 | Multi-layer substrate for semiconductor packaging |
EP2787076A4 (en) * | 2011-09-30 | 2015-07-01 | Tokyo Metropolitan Inst Medical Science | Method for evaluating drug sensitivity and susceptibility to diseases by analyzing gene for protein capable of binding to cyclic-amp-responsive sequence |
WO2016134049A1 (en) * | 2015-02-17 | 2016-08-25 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
US10570453B2 (en) | 2007-03-29 | 2020-02-25 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to QT prolongation |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010324810B2 (en) * | 2009-11-27 | 2016-05-12 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
CA3051829A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
KR20200066661A (en) | 2017-10-10 | 2020-06-10 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Methods of administering certain VMAT2 inhibitors |
US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
US11737858B2 (en) | 2018-11-14 | 2023-08-29 | Terry B. Philibin | Healing abutment system for configuring crown abutments at an implant site |
US11607408B2 (en) | 2019-10-15 | 2023-03-21 | Vanda Pharmaceuticals Inc. | Method of treatment of schizophrenia |
WO2023201182A1 (en) | 2022-04-13 | 2023-10-19 | Vanda Pharmaceuticals Inc. | Treatment of parkinson's disease and parkinson's disease psychosis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
WO2002064141A1 (en) | 2001-02-05 | 2002-08-22 | Novartis Ag | New use of iloperidone |
WO2003038123A2 (en) | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
US20030091645A1 (en) | 2001-10-30 | 2003-05-15 | Markus Ahlheim | Organic compounds |
WO2003054226A2 (en) | 2001-12-10 | 2003-07-03 | Novartis Ag | Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
WO2004009760A2 (en) | 2002-07-18 | 2004-01-29 | Bioventures, Inc. | Cytochrome p450 genetic variations |
US20040091909A1 (en) | 2002-07-05 | 2004-05-13 | Huang Doug Hui | High throughput cytochrome P450 genotyping |
US20040096874A1 (en) | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
CH676470A5 (en) | 1988-02-03 | 1991-01-31 | Nestle Sa | |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
GB9001181D0 (en) * | 1990-01-18 | 1990-03-21 | Imp Cancer Res Tech | Genetic assay |
JP2002539450A (en) * | 1999-03-15 | 2002-11-19 | レイランド−ジョーンズ,ブライアン | ELISA kit for metabolic phenotyping |
AP2001002290A0 (en) * | 1999-04-07 | 2001-12-31 | Pfizer Prod Inc | Use of CYP2D6 inhibitors in combination therapies. |
US20010034023A1 (en) | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US7250252B2 (en) | 1999-12-30 | 2007-07-31 | David Aaron Katz | Amplification based polymorphism detection |
ATE381626T1 (en) | 2000-04-13 | 2008-01-15 | Univ Georgetown | GENETIC DIAGNOSIS TO DETERMINE QT PROLONGATION AS AN ADVERSE REACTION TO DRUGS |
US6761895B2 (en) | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
WO2001096604A2 (en) * | 2000-06-12 | 2001-12-20 | Genicon Sciences Corporation | Assay for genetic polymorphisms using scattered light detectable labels |
US20020022254A1 (en) | 2000-07-28 | 2002-02-21 | Karl Guegler | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
EP1364334A2 (en) | 2000-11-30 | 2003-11-26 | Third Wave Technologies, Inc. | Systems and method for detection assay production and sale |
AU2002244568A1 (en) | 2001-03-14 | 2002-09-24 | Mcgill University | Individualization of therapy with antipsychotics |
CA2449752A1 (en) * | 2001-06-05 | 2002-12-12 | Genaissance Pharmaceuticals, Inc. | Method of identifying a polymorphism in cyp2d6 |
US7195877B2 (en) | 2001-07-20 | 2007-03-27 | Bioventures, Inc. | Cytochrome P450 genetic variations |
EP1281755A3 (en) * | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
EP1425030A2 (en) | 2001-08-24 | 2004-06-09 | Aryx Therapeutics | Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
JP2005504783A (en) | 2001-08-31 | 2005-02-17 | ノバルティス アクチエンゲゼルシャフト | Optical isomers of iloperidone metabolites |
AT6081U1 (en) | 2001-12-21 | 2003-04-25 | Steyr Powertrain Ag & Co Kg | SWITCHING DEVICE FOR A GEARBOX AND DISTRIBUTION GEARBOX OF A MOTOR VEHICLE WITH SUCH A GEARBOX |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
ES2575903T3 (en) | 2003-02-20 | 2016-07-04 | Mayo Foundation For Medical Education And Research | Methods to select antidepressant medications |
US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
EP1747467A1 (en) | 2004-05-11 | 2007-01-31 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 6 (dpp6) |
EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
ES2542967T3 (en) * | 2007-03-29 | 2015-08-13 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to QT prolongation |
ES2681240T3 (en) | 2007-05-18 | 2018-09-12 | Vanda Pharmaceuticals Inc. | Genetic markers of iloperidone efficacy in the treatment of psychotic symptoms |
WO2010117937A1 (en) * | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation |
JP5692872B2 (en) * | 2009-04-06 | 2015-04-01 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Method for predicting predisposition to QT prolongation based on BAI gene sequence or product thereof |
US9074256B2 (en) * | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
-
2005
- 2005-09-30 EP EP05803436A patent/EP1799865B1/en active Active
- 2005-09-30 ES ES12164353T patent/ES2825949T3/en active Active
- 2005-09-30 CA CA2582022A patent/CA2582022C/en active Active
- 2005-09-30 CA CA3113166A patent/CA3113166A1/en active Pending
- 2005-09-30 WO PCT/US2005/035526 patent/WO2006039663A2/en active Application Filing
- 2005-09-30 EP EP12164353.0A patent/EP2479290B1/en active Active
- 2005-09-30 JP JP2007534871A patent/JP2008514731A/en active Pending
- 2005-09-30 US US11/576,178 patent/US8586610B2/en active Active
- 2005-09-30 AU AU2005292246A patent/AU2005292246B2/en active Active
-
2013
- 2013-10-23 US US14/060,978 patent/US20140045893A1/en not_active Abandoned
-
2014
- 2014-01-08 US US14/150,575 patent/US9138432B2/en active Active
- 2014-03-05 JP JP2014042711A patent/JP5829707B2/en active Active
-
2015
- 2015-05-13 US US14/710,817 patent/US20150258083A1/en not_active Abandoned
-
2017
- 2017-12-08 US US15/835,872 patent/US10272076B2/en active Active
-
2019
- 2019-02-27 US US16/286,878 patent/US20190183873A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,113 patent/US20200206213A1/en not_active Abandoned
-
2021
- 2021-03-03 US US17/190,934 patent/US20210186948A1/en not_active Abandoned
-
2023
- 2023-05-15 US US18/317,881 patent/US20230330078A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
US6001567A (en) | 1996-01-24 | 1999-12-14 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
WO2002064141A1 (en) | 2001-02-05 | 2002-08-22 | Novartis Ag | New use of iloperidone |
US20030091645A1 (en) | 2001-10-30 | 2003-05-15 | Markus Ahlheim | Organic compounds |
WO2003038123A2 (en) | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
WO2003054226A2 (en) | 2001-12-10 | 2003-07-03 | Novartis Ag | Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
US20040096874A1 (en) | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
US20040091909A1 (en) | 2002-07-05 | 2004-05-13 | Huang Doug Hui | High throughput cytochrome P450 genotyping |
WO2004009760A2 (en) | 2002-07-18 | 2004-01-29 | Bioventures, Inc. | Cytochrome p450 genetic variations |
Non-Patent Citations (4)
Title |
---|
LYAMICHEV, NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 292 - 296 |
NATARAYAN, RECEPTOR PROFILE, 2002, pages 88 - 8991 |
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 26, pages 553 - 560 |
RYAN ET AL., MOLECULAR DIAGNOSIS, vol. 4, no. 2, 1999, pages 135 - 144 |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9138432B2 (en) | 2004-09-30 | 2015-09-22 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
US8586610B2 (en) | 2004-09-30 | 2013-11-19 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
US10272076B2 (en) | 2004-09-30 | 2019-04-30 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
EP2029136A4 (en) * | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | Treatment for depressive disorders |
WO2007137227A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
EP2029136A1 (en) * | 2006-05-22 | 2009-03-04 | Vanda Pharmaceuticals Inc. | Treatment for depressive disorders |
US10570453B2 (en) | 2007-03-29 | 2020-02-25 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to QT prolongation |
US9074254B2 (en) | 2007-03-29 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
WO2008121899A3 (en) * | 2007-03-29 | 2008-12-31 | Vanda Pharmaceuticals Inc | Method of predicting a predisposition to qt prolongation |
WO2008121899A2 (en) | 2007-03-29 | 2008-10-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
US8198305B2 (en) | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
EP3075865A2 (en) | 2007-05-18 | 2016-10-05 | Vanda Pharmaceuticals Inc. | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
US9080214B2 (en) | 2007-05-18 | 2015-07-14 | Vanda Pharmaceuticals, Inc. | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
WO2008144599A3 (en) * | 2007-05-18 | 2009-01-29 | Vanda Pharmaceuticals Inc | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
WO2009036056A1 (en) * | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
US9328387B2 (en) | 2007-09-10 | 2016-05-03 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on SNP genotype |
JP2010538617A (en) * | 2007-09-10 | 2010-12-16 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Prediction of QT prolongation based on SNP genotype |
JP2010538615A (en) * | 2007-09-10 | 2010-12-16 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Antipsychotic treatment based on SNP genotype |
US9458507B1 (en) | 2007-09-10 | 2016-10-04 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on SNP genotype |
WO2009076663A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
JP2011506481A (en) * | 2007-12-13 | 2011-03-03 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Methods and compositions for treating alpha adrenergic receptor mediated conditions |
US9987264B2 (en) | 2007-12-13 | 2018-06-05 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
US8618134B2 (en) | 2007-12-13 | 2013-12-31 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
US8729100B2 (en) | 2007-12-13 | 2014-05-20 | Vanda Pharmaceuticals, Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
AU2008334932B2 (en) * | 2007-12-13 | 2014-05-22 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
US9446038B2 (en) | 2007-12-13 | 2016-09-20 | Vanda Pharmaceuticals, Inc. | Method and composition for treating a serotonin receptor-mediated condition |
US10272075B2 (en) | 2007-12-13 | 2019-04-30 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
AU2008334933B2 (en) * | 2007-12-13 | 2016-01-21 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
WO2009076664A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
EP3492081A1 (en) * | 2008-09-10 | 2019-06-05 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
WO2010030783A1 (en) | 2008-09-10 | 2010-03-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
US9074255B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
JP2012522533A (en) * | 2009-04-06 | 2012-09-27 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | How to predict a predisposition to QT prolongation |
US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
US10563259B2 (en) | 2009-04-06 | 2020-02-18 | Vanda Pharmeceuticals, Inc. | Method of treatment based on polymorphisms of the KCNQ1 gene |
US9157121B2 (en) | 2009-04-06 | 2015-10-13 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the KCNQ1 gene |
US10563261B2 (en) | 2009-04-06 | 2020-02-18 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
US10563260B2 (en) | 2009-04-06 | 2020-02-18 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
US8999638B2 (en) | 2009-04-06 | 2015-04-07 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the KCNQ1 gene |
EP3023506A1 (en) | 2009-04-06 | 2016-05-25 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
US10570452B2 (en) | 2009-04-06 | 2020-02-25 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
WO2010117941A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
WO2010117943A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof |
WO2010117937A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation |
WO2010117931A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
EP3354753A1 (en) | 2009-04-06 | 2018-08-01 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
US9074256B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
WO2010132866A1 (en) * | 2009-05-15 | 2010-11-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
US9408839B2 (en) | 2009-05-15 | 2016-08-09 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype |
US9243295B2 (en) | 2009-05-15 | 2016-01-26 | Vanda Pharmaceutical, Inc. | Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype |
US9057104B2 (en) | 2009-05-15 | 2015-06-16 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype |
US9727691B2 (en) | 2011-09-30 | 2017-08-08 | Tokyo Metropolitan Institute Of Medical Science | Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene |
EP2787076A4 (en) * | 2011-09-30 | 2015-07-01 | Tokyo Metropolitan Inst Medical Science | Method for evaluating drug sensitivity and susceptibility to diseases by analyzing gene for protein capable of binding to cyclic-amp-responsive sequence |
EP3345603A1 (en) | 2012-03-14 | 2018-07-11 | Vanda Pharmaceuticals Inc. | Iloperidone metabolite for use in the treatment of psychiatric disorders |
WO2013138602A1 (en) | 2012-03-14 | 2013-09-19 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
US10874659B2 (en) | 2012-03-14 | 2020-12-29 | Vanda Pharmaceuticals Inc. | Iloperidone metabolite for use in the treatment of psychiatric disorders |
CN104254917A (en) * | 2012-03-26 | 2014-12-31 | 先进封装技术私人有限公司 | Multi-layer substrate for semiconductor packaging |
CN107249586A (en) * | 2015-02-17 | 2017-10-13 | 万达制药公司 | For treating schizoid Iloperidone |
US10441580B2 (en) | 2015-02-17 | 2019-10-15 | Vanda Pharmaceuticals, Inc. | Iloperidone for the treatment of schizophrenia |
WO2016134049A1 (en) * | 2015-02-17 | 2016-08-25 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
US10987346B2 (en) | 2015-02-17 | 2021-04-27 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
Also Published As
Publication number | Publication date |
---|---|
JP2014129403A (en) | 2014-07-10 |
JP5829707B2 (en) | 2015-12-09 |
US20200206213A1 (en) | 2020-07-02 |
CA3113166A1 (en) | 2006-04-13 |
US20190183873A1 (en) | 2019-06-20 |
US10272076B2 (en) | 2019-04-30 |
EP1799865B1 (en) | 2012-06-06 |
CA2582022A1 (en) | 2006-04-13 |
JP2008514731A (en) | 2008-05-08 |
CA2582022C (en) | 2021-05-18 |
US9138432B2 (en) | 2015-09-22 |
EP2479290B1 (en) | 2020-08-19 |
AU2005292246A1 (en) | 2006-04-13 |
US20230330078A1 (en) | 2023-10-19 |
US20090298880A1 (en) | 2009-12-03 |
EP2479290A3 (en) | 2012-10-10 |
EP1799865A2 (en) | 2007-06-27 |
US20180110765A1 (en) | 2018-04-26 |
US20140128433A1 (en) | 2014-05-08 |
AU2005292246B2 (en) | 2011-07-07 |
US8586610B2 (en) | 2013-11-19 |
US20150258083A1 (en) | 2015-09-17 |
WO2006039663A3 (en) | 2006-11-02 |
US20140045893A1 (en) | 2014-02-13 |
EP2479290A2 (en) | 2012-07-25 |
ES2825949T3 (en) | 2021-05-17 |
EP1799865A4 (en) | 2008-03-05 |
US20210186948A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10272076B2 (en) | Methods for the administration of iloperidone | |
US20220259660A1 (en) | Methods for the administration of iloperidone | |
Campbell et al. | Polymorphisms in the GTP cyclohydrolase gene (GCH1) are associated with ratings of capsaicin pain | |
JP6528158B2 (en) | Antipsychotic treatment based on SNP genotype of DRD2 or ANKK1 | |
JP5560456B2 (en) | How to determine the side effects or efficacy of erlotinib | |
AU2004283234B2 (en) | Use of genetic polymorphisms to predict drug-induced hepatotoxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2582022 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11576178 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005292246 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007534871 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005292246 Country of ref document: AU Date of ref document: 20050930 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005292246 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005803436 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005803436 Country of ref document: EP |